Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Sean Arora, MD - a board-certified physician licensed in all 50 states and the founder and CEO of Arora Health
Clinical trial data reports improved glycemic control despite glucagon activation, making it a practical tool for studying glucagon-mediated energy expenditure independently of hyperglycemic confounds
What was once available only to people with excellent insurance or substantial disposable income becomes accessible to a much broader population who can benefit from effective weight loss treatment
This price difference could mean big savings for both you and your members a win-win situation
Compounded semaglutide and tirzepatide remain the most affordable GLP-1 options for self-pay patients in 2026
Phase 2 trial data (NEJM, 2023) showed a mean body weight reduction of approximately 24% at the highest dose (12 mg weekly) over 48 weeks in adults without type 2 diabetes
US$ 28.31
US$ 24.43
US$ 22.27
US$ 26.24
US$ 21.14
US$ 26.41
US$ 28.07
US$ 23.08
US$ 23.76
US$ 28.36
